Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: data of the German KIMS cohort

Research output: Journal contributionsJournal articlesResearch

Standard

Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: data of the German KIMS cohort. / Moock, Joern; Friedrich, Nele; Völzke, Henry et al.
In: Growth Hormone and IGF Research, Vol. 21, No. 5, 01.10.2011, p. 272-278.

Research output: Journal contributionsJournal articlesResearch

Harvard

Moock, J, Friedrich, N, Völzke, H, Spielhagen, C, Nauck, M, Koltowska-Häggström, M, Buchfelder, M, Wallaschofski, H & Kohlmann, T 2011, 'Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: data of the German KIMS cohort', Growth Hormone and IGF Research, vol. 21, no. 5, pp. 272-278. https://doi.org/10.1016/j.ghir.2011.07.005

APA

Moock, J., Friedrich, N., Völzke, H., Spielhagen, C., Nauck, M., Koltowska-Häggström, M., Buchfelder, M., Wallaschofski, H., & Kohlmann, T. (2011). Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: data of the German KIMS cohort. Growth Hormone and IGF Research, 21(5), 272-278. https://doi.org/10.1016/j.ghir.2011.07.005

Vancouver

Moock J, Friedrich N, Völzke H, Spielhagen C, Nauck M, Koltowska-Häggström M et al. Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: data of the German KIMS cohort. Growth Hormone and IGF Research. 2011 Oct 1;21(5):272-278. doi: 10.1016/j.ghir.2011.07.005

Bibtex

@article{5f23e170e9594517ab42639e31c736d3,
title = "Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: data of the German KIMS cohort",
abstract = "Objective: The objective of the present study was to calculate sex- and age-specific normative values for health-related quality of life (HRQoL) in Germany using quantile regression. Furthermore, we investigate the estimates of these normative data to and to predict the improvement of QoL-AGHDA scores in the German KIMS cohort during growth hormone treatment. Design: Normative data of HRQoL was assessed by quality of life assessment of growth hormone deficiency (GHD) in adults (QoL-AGHDA) in a representative sample of the German population (n = 4172). Corresponding data for 888 patients with GHD were retrieved from the German KIMS cohort (Pfizer International Metabolic Database). Results: The overall mean QoL-AGHDA score of the general population was 4.8 ± 5.2. ANOVA indicated that variability in QoL-AGHDA scores did not differ significantly across gender (p = 0.20), whereas age was a significant predictor (p < 0.001). Given the QoL-AGHDA score distribution of the general population, we calculated reference values based on quantile regression. In KIMS patients we observed significantly higher QoL-AGHDA scores, 7.9 ± 6.5 (p < 0.001), before GH treatment. The optimal predictive QoL-AGHDA score was 6 (70th percentile) with a sensitivity of 0.57 and a specificity of 0.70 in ROC analysis. Furthermore, a baseline QoL-AGHDA score above the 70th percentile allowed predicting an improvement of QoL by GH treatment. Conclusions: This study established normative reference values for the QoL-AGHDA in a representative sample of the German population. Based on these normative data a QoL-AGHDA cut-off value for prediction of improvement was investigated for the German population, which may facilitate clinical assessment of HRQoL response to GH replacement for patients with GHD.",
keywords = "Health sciences, Quality of life, growth hormone dificiency, normative reference values, quantile regression",
author = "Joern Moock and Nele Friedrich and Henry V{\"o}lzke and Christin Spielhagen and Matthias Nauck and Maria Koltowska-H{\"a}ggstr{\"o}m and Michael Buchfelder and Henri Wallaschofski and Thomas Kohlmann",
note = "Copyright {\textcopyright} 2011 Elsevier Ltd. All rights reserved.",
year = "2011",
month = oct,
day = "1",
doi = "10.1016/j.ghir.2011.07.005",
language = "English",
volume = "21",
pages = "272--278",
journal = "Growth Hormone and IGF Research",
issn = "1096-6374",
publisher = "Churchill Livingstone",
number = "5",

}

RIS

TY - JOUR

T1 - Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: data of the German KIMS cohort

AU - Moock, Joern

AU - Friedrich, Nele

AU - Völzke, Henry

AU - Spielhagen, Christin

AU - Nauck, Matthias

AU - Koltowska-Häggström, Maria

AU - Buchfelder, Michael

AU - Wallaschofski, Henri

AU - Kohlmann, Thomas

N1 - Copyright © 2011 Elsevier Ltd. All rights reserved.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Objective: The objective of the present study was to calculate sex- and age-specific normative values for health-related quality of life (HRQoL) in Germany using quantile regression. Furthermore, we investigate the estimates of these normative data to and to predict the improvement of QoL-AGHDA scores in the German KIMS cohort during growth hormone treatment. Design: Normative data of HRQoL was assessed by quality of life assessment of growth hormone deficiency (GHD) in adults (QoL-AGHDA) in a representative sample of the German population (n = 4172). Corresponding data for 888 patients with GHD were retrieved from the German KIMS cohort (Pfizer International Metabolic Database). Results: The overall mean QoL-AGHDA score of the general population was 4.8 ± 5.2. ANOVA indicated that variability in QoL-AGHDA scores did not differ significantly across gender (p = 0.20), whereas age was a significant predictor (p < 0.001). Given the QoL-AGHDA score distribution of the general population, we calculated reference values based on quantile regression. In KIMS patients we observed significantly higher QoL-AGHDA scores, 7.9 ± 6.5 (p < 0.001), before GH treatment. The optimal predictive QoL-AGHDA score was 6 (70th percentile) with a sensitivity of 0.57 and a specificity of 0.70 in ROC analysis. Furthermore, a baseline QoL-AGHDA score above the 70th percentile allowed predicting an improvement of QoL by GH treatment. Conclusions: This study established normative reference values for the QoL-AGHDA in a representative sample of the German population. Based on these normative data a QoL-AGHDA cut-off value for prediction of improvement was investigated for the German population, which may facilitate clinical assessment of HRQoL response to GH replacement for patients with GHD.

AB - Objective: The objective of the present study was to calculate sex- and age-specific normative values for health-related quality of life (HRQoL) in Germany using quantile regression. Furthermore, we investigate the estimates of these normative data to and to predict the improvement of QoL-AGHDA scores in the German KIMS cohort during growth hormone treatment. Design: Normative data of HRQoL was assessed by quality of life assessment of growth hormone deficiency (GHD) in adults (QoL-AGHDA) in a representative sample of the German population (n = 4172). Corresponding data for 888 patients with GHD were retrieved from the German KIMS cohort (Pfizer International Metabolic Database). Results: The overall mean QoL-AGHDA score of the general population was 4.8 ± 5.2. ANOVA indicated that variability in QoL-AGHDA scores did not differ significantly across gender (p = 0.20), whereas age was a significant predictor (p < 0.001). Given the QoL-AGHDA score distribution of the general population, we calculated reference values based on quantile regression. In KIMS patients we observed significantly higher QoL-AGHDA scores, 7.9 ± 6.5 (p < 0.001), before GH treatment. The optimal predictive QoL-AGHDA score was 6 (70th percentile) with a sensitivity of 0.57 and a specificity of 0.70 in ROC analysis. Furthermore, a baseline QoL-AGHDA score above the 70th percentile allowed predicting an improvement of QoL by GH treatment. Conclusions: This study established normative reference values for the QoL-AGHDA in a representative sample of the German population. Based on these normative data a QoL-AGHDA cut-off value for prediction of improvement was investigated for the German population, which may facilitate clinical assessment of HRQoL response to GH replacement for patients with GHD.

KW - Health sciences

KW - Quality of life

KW - growth hormone dificiency

KW - normative reference values

KW - quantile regression

UR - http://www.scopus.com/inward/record.url?scp=80052572912&partnerID=8YFLogxK

U2 - 10.1016/j.ghir.2011.07.005

DO - 10.1016/j.ghir.2011.07.005

M3 - Journal articles

C2 - 21865066

VL - 21

SP - 272

EP - 278

JO - Growth Hormone and IGF Research

JF - Growth Hormone and IGF Research

SN - 1096-6374

IS - 5

ER -